Elanco raises 2026 revenue and profit outlook on Zenrelia and Credelio Quattro strength

Elanco Animal Health reported financial results for the second quarter of 2026 on August 5, 2026, and updated its guidance for the full year with revenue of $1,368 million, an increase of 10% year-over-year, or 8% organic constant currency growth.¹

CEO Jeff Simmons said Zenrelia, described as the company's newest blockbuster, was the single largest contributor to global Elanco growth, closely followed by Credelio Quattro.¹ The company said Zenrelia achieved blockbuster status through July year to date, with efficacy driving use in approximately 18,000 U.S. clinics, and U.S. JAK market share up 9 points year-over-year.¹ Credelio Quattro also gained ground, as the product penetrated over 50% of the U.S. clinic base, up approximately 3,000 clinics representing 10 points versus the first quarter, and launched in Australia, Canada, and Japan to date.¹ A newer product, Befrena, shipped to nearly 1,400 U.S. clinics to date, with the company ramping capacity to meet high customer demand 2x above expectations.¹

On guidance, Elanco raised its full-year revenue target to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth, and raised Adjusted EBITDA guidance to $1.01 billion to $1.035 billion.¹ The company also said it is raising its innovation revenue target to $1.25 billion and improving its year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA.¹ CFO Bob VanHimbergen said the company is making good early progress on its Elanco Ascend productivity initiatives, on track to $200 million to $250 million in adjusted EBITDA net savings by 2030, and that with a net leverage ratio of 3.1x at quarter-end, the company is closing in on its target of reaching below 3x next year.¹

For the third quarter, Elanco guided to revenue of $1,195 million to $1,220 million, Adjusted EBITDA of $200 million to $215 million, and Adjusted Earnings per Share of $0.19 to $0.22.¹